MX2018006247A - Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. - Google Patents

Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.

Info

Publication number
MX2018006247A
MX2018006247A MX2018006247A MX2018006247A MX2018006247A MX 2018006247 A MX2018006247 A MX 2018006247A MX 2018006247 A MX2018006247 A MX 2018006247A MX 2018006247 A MX2018006247 A MX 2018006247A MX 2018006247 A MX2018006247 A MX 2018006247A
Authority
MX
Mexico
Prior art keywords
disease
treating alzheimer
methods
related disorders
cromolyn
Prior art date
Application number
MX2018006247A
Other languages
English (en)
Inventor
Elmaleh David
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of MX2018006247A publication Critical patent/MX2018006247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está dirigida a un método para tratar la Enfermedad de Alzheimer al administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de cromolina y opcionalmente ibuprofeno. La cromolina puede ser en forma de cromolina sódica y se administra por inhalación.
MX2018006247A 2015-11-19 2016-11-21 Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. MX2018006247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257616P 2015-11-19 2015-11-19
PCT/US2016/063143 WO2017087962A1 (en) 2015-11-19 2016-11-21 Methods for treating alzheimer's disease and related disorders

Publications (1)

Publication Number Publication Date
MX2018006247A true MX2018006247A (es) 2018-11-29

Family

ID=58717951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006247A MX2018006247A (es) 2015-11-19 2016-11-21 Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.

Country Status (9)

Country Link
US (2) US20180325862A1 (es)
EP (1) EP3377118A4 (es)
JP (1) JP2018534336A (es)
KR (1) KR20180081807A (es)
CN (2) CN108472393A (es)
AU (1) AU2016355594A1 (es)
CA (1) CA3005887A1 (es)
MX (1) MX2018006247A (es)
WO (1) WO2017087962A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CN111565711B (zh) * 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
AU2019336698A1 (en) * 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CA2751125C (en) * 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10058530B2 (en) * 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh) * 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
CA2913235C (en) * 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
PT3104853T (pt) * 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos

Also Published As

Publication number Publication date
CN108472393A (zh) 2018-08-31
CN114042061A (zh) 2022-02-15
KR20180081807A (ko) 2018-07-17
US20200338040A1 (en) 2020-10-29
EP3377118A4 (en) 2019-07-10
US20180325862A1 (en) 2018-11-15
WO2017087962A1 (en) 2017-05-26
CA3005887A1 (en) 2017-05-26
JP2018534336A (ja) 2018-11-22
AU2016355594A1 (en) 2018-06-14
EP3377118A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
IN2015DN00376A (es)
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
BR112015022197A2 (pt) tratamento de cataplexia
BR112014010803A2 (pt) método de tratamento
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
IN2015DN00450A (es)
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
PH12016502352A1 (en) Pharmaceutical composition
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.